ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Retention of apolipoprotein (apo)B and apoE-containing lipoproteins by extracellular vascular proteoglycans is critical in atherogenesis. Moreover, high circulating apoC-III levels are associated with increased atherosclerosis risk. To test whether apoC-III content of apoB-containing lipoproteins affects their ability to bind to the vascular proteoglycan biglycan, we evaluated the impact of apoC-III on the interaction of [(35)S]SO(4)-biglycan derived from cultured arterial smooth muscle cells with lipoproteins obtained from individuals across a spectrum of lipid concentrations. The extent of biglycan binding correlated positively with apoC-III levels within VLDL (r = 0.78, P < 0.01), IDL (r = 0.67, P < 0.01), and LDL (r = 0.52, P < 0.05). Moreover, the biglycan binding of VLDL, IDL, and LDL was reduced after depletion of apoC-III-containing lipoprotein particles in plasma by anti-apoC-III immunoaffinity chromatography. Since apoC-III does not bind biglycan directly, enhanced biglycan binding may result from a conformational change associated with increased apo C-III content by which apoB and/or apoE become more accessible to proteoglycans. This may be an intrinsic property of lipoproteins, since exogenous apoC-III enrichment of LDL and VLDL did not increase binding. ApoC-III content may thus be a marker for lipoproteins characterized as having an increased ability to bind proteoglycans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 LDL binds to biglycan with high affinity. A: Autoradiograph of a gel from the electrophoretic gel mobility shift assay is shown. Increasing concentrations of VLDL, IDL, and LDL from a subject were incubated with a fixed amount (0.19 𝛍 M) of [ 35 S]SO4-labeled biglycan for 1 h at 37 ° C prior to electrophoresis in agarose, as described in Materials and Methods. Biglycan that binds lipoproteins remains at the origin, or migrates a short distance into the gel. Free, unbound [ 35 S]SO4-biglycan migrates to the front of the gel. B: The binding curves for the interaction of VLDL (circle), IDL (square), and LDL (triangle) and [ 35 S]SO4-labeled biglycan that were shown in A. The amount of bound versus free [ 35 S]SO4-biglycan for each lane was calculated, and plotted against the concentration of total protein for that lipoprotein sample. The inset shows the same data as a Scatchard plot. Data are from a single experiment that is representative of lipoprotein samples from 24 subjects.](https://figures.cochat.ai/paper-figures/47acf12c2c17455b9e5b69f9a1c02a91/apoc-iii-content-of-apob-containing-lipoproteins-is-associated-with-binding-to-figure-1.png)
![Fig. 2 Within each lipoprotein class, the amount of apoC-III correlates positively with the ability of the lipoprotein to bind biglycan. Hyperbolic regression curves are shown to demonstrate the correlation of a lipoprotein's apoC-III content with the amount of biglycan bound to samples of lipoprotein (VLDL, circle; IDL, square; LDL, triangle) that contained 0.05 mg/ml total protein. For the interaction, samples were incubated with a fixed amount (0.19 𝛍 M) of [ 35 S]SO4-labeled biglycan for 1 h at 37 ° C prior to electrophoresis in agarose, as described in Materials and Methods.](https://figures.cochat.ai/paper-figures/6d564be98af9412eabaaf31603a5bd49/apoc-iii-content-of-apob-containing-lipoproteins-is-associated-with-binding-to-figure-2.png)
![Fig. 3 Within each lipoprotein class, the amount of apoC-III correlates with the affinity constant ( Ka ) for the interaction of the lipoprotein with biglycan. Hyperbolic regression curves are shown to demonstrate the correlation of a lipoprotein's apoC-III content with the affinity constant ( Ka ) calculated from the interaction with biglycan (VLDL, circle; IDL, square; LDL, triangle). For the interaction, samples were incubated with a fixed amount (0.19 𝛍 M) of [ 35 S]SO4-labeled biglycan for 1 h at 37 ° C prior to electrophoresis in agarose, as described in Materials and Methods.](https://figures.cochat.ai/paper-figures/1d4dc0f8e7f64d03bb874756cda7f58a/apoc-iii-content-of-apob-containing-lipoproteins-is-associated-with-binding-to-figure-3.png)
![Fig. 4 Increased binding of biglycan to lipoproteins that contain apoC-III compared to apoC-III-depleted lipoproteins. Binding curves are shown for the interaction of biglycan and apoC-III-containing (A) VLDL, (B) IDL, and (C) LDL (open circle), or VLDL, IDL, and LDL isolated from the same plasma sample that had been passed over an anti-human apoC-III column (closed circle). Equal numbers of lipoprotein particles were incubated with a fixed amount (0.19 𝛍 M) of [ 35 S]SO4-labeled biglycan for 1 h at 37 ° C prior to electrophoresis in agarose, as described in Materials and Methods. The insets show the same data as Scatchard plots. The data are from a single experiment that is representative of two independent experiments.](https://figures.cochat.ai/paper-figures/68456f2f4ec547ad8bf3dfad19e053f3/apoc-iii-content-of-apob-containing-lipoproteins-is-associated-with-binding-to-figure-4.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“VLDL and remnants are also enriched in apoE and apoCIII, both implicated in binding and retention in the artery wall.5,71,125”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331 · cited 1×
“LDL protein concentrations were determined by a modification of the method of Lowry, et al. ( 25 ) using BSA as the standard.”
MethodPhosphorus Assay in Column Chromatography
Bartlett, G. R. (1959) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)70226-3 · Cited by 12,801 · cited 1×
“Phospholipids were measured using a standardized colorimetric method (24) and a phosphorous calibrator (Sigma Chem.”
MethodThe Response-to-Retention Hypothesis of Early Atherogenesis
Williams, K. J., & Tabas, I. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.551 · Cited by 1,413 · cited 1×
“Kinetic analyses suggest that the trapping of lipoproteins by arterial wall proteoglycans is due to selective retention rather than increased delivery of the lipoproteins (4, 8).”
BackgroundMolecular modeling of protein-glycosaminoglycan interactions.
Cardin, A. D., & Weintraub, H. J. (1989) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.9.1.21 · Cited by 1,301 · cited 3×
“This is consistent with the presence of heparin/proteoglycan binding regions on both apoB and apoE (5, 36 ).”
BackgroundResultInfluentialFisher, L. W., Termine, J. D., & Young, M. F. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83781-4 · Cited by 702
Mahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693
Blood Lipids and Lipoproteins: Quantitation, Composition and Metabolism
(1973) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1973.tb128705.x · Cited by 554
Chait, A., Brazg, R. L., Tribble, D. L., & Krauss, R. M. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90144-e · Cited by 554 · cited 1×
“Along with being more susceptible to oxidative modification than large LDL (50, 51), small, dense LDL particles have been hypothesized to have greater permeability and have been suggested to have enhanced affinity for arterial wall proteoglycans (7, 52).”
BackgroundSelf-citation[24] Nondenaturing polyacrylamide gradient gel electrophoresis
Nichols, A. V., Krauss, R. M., & Musliner, T. A. (1986) · Methods in Enzymology · doi:10.1016/0076-6879(86)28084-2 · Cited by 521 · cited 1×
“Particle size measurement of apoB-containing lipoproteins was performed on plasma and isolated lipoprotein fractions using non-denaturing 2–14% polyacrylamide gradient gel electrophoresis (GGE) and standardized conditions (23).”
MethodSelf-citationSuperoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells.
Heinecke, J. W., Baker, L., Rosen, H., & Chait, A. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112371 · Cited by 517
Self-citationSacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490
Aalto-Setälä, K., Fisher, E. A., Chen, X., Chajek-Shaul, T., Hayek, T., Zechner, R., Walsh, A., Ramakrishnan, R., Ginsberg, H. N., & Breslow, J. L. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116066 · Cited by 450
Blood lipids and lipoproteins; quantitation, composition and metabolism
Schonfeld, G. (1973) · Journal of Chronic Diseases · doi:10.1016/0021-9681(73)90041-6 · Cited by 399 · cited 1×
“Lipoprotein fractions (VLDL, IDL, and LDL) then were prepared from total and apoC-III-depleted plasma by sequential ultracentrifugation, as described previously (29).”
MethodSchwenke, D. C., & Carew, T. E. (1989) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.9.6.908 · Cited by 343
Borén, J., Olin, K., Lee, I., Chait, A., Wight, T. N., & Innerarity, T. L. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2265 · Cited by 320
Self-citationO’Brien, K. D., Olin, K. L., Alpers, C. E., Chiu, W., Ferguson, M., Hudkins, K., Wight, T. N., & Chait, A. (1998) · Circulation · doi:10.1161/01.cir.98.6.519 · Cited by 271 · cited 3×
“Consistent with this we have shown that apoE-free HDL, which contain abundant apoC-III, do not bind to proteoglycans(13, 14), thus further indicating that apoCIII does not bind directly to proteoglycans.”
BackgroundSelf-citation[45] Proteoglycans: Isolation and Characterization
Hascall, V. C., & Kimura, J. H. (1982) · Methods in Enzymology · doi:10.1016/0076-6879(82)82102-2 · Cited by 260
Anber, V., Griffin, B. A., McConnell, M., Packard, C. J., & Shepherd, J. (1996) · Atherosclerosis · doi:10.1016/0021-9150(96)05842-x · Cited by 238 · cited 1×
“Along with being more susceptible to oxidative modification than large LDL (50, 51), small, dense LDL particles have been hypothesized to have greater permeability and have been suggested to have enhanced affinity for arterial wall proteoglycans (7, 52 ).”
BackgroundCAMEJO, G. (1982) · Advances in Lipid Research · doi:10.1016/b978-0-12-024919-0.50007-2 · Cited by 230
Atherogenicity of Triglyceride-Rich Lipoproteins
Krauss, R. M. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00032-0 · Cited by 227 · cited 1×
“In normotriglyceridemic subjects, apoC-III is associated primarily with HDL; however, there is redistribution of apoC-III to VLDL and a concomitant increase in total plasma levels of apoC-III in hypertriglyceridemia (15, 38).”
BackgroundSelf-citationWilliams, K. J., Fless, G. M., Petrie, K. A., Snyder, M. L., Brocia, R. W., & Swenson, T. L. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42208-9 · Cited by 205
The Isolation and Quantitative Analysis of Serum Lipoproteins
Lindgren, F. T., Jensen, L. C., & Hatch, F. T. (2023) · eScholarship (California Digital Library) · Cited by 200
Brewer, H. B., Shulman, R., Herbert, P., Ronan, R., & Wehrly, K. (1974) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)42416-2 · Cited by 199
Camejo, G., Olofsson, S. O., Lopez, F., Carlsson, P., & Bondjers, G. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.4.368 · Cited by 198
Clavey, V., Lestavel-Delattre, S., Copin, C., Bard, J. M., & Fruchart, J. C. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.7.963 · Cited by 178
Hurt-Camejo, E., Olsson, U., Wiklund, O., Bondjers, G., & Camejo, G. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.6.1011 · Cited by 165 · cited 3×
“These data are consistent with the idea that the interaction between lipoproteins and proteoglycans is ionic in nature, such that lipoproteins with greater positive charge bind better to negatively charged glycosaminoglycan side chains on proteoglycans (6, 7, 36).”
BackgroundResultTribble, D. L., van den Berg, J. J., Motchnik, P. A., Ames, B. N., Lewis, D. M., Chait, A., & Krauss, R. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.3.1183 · Cited by 163
Self-citationHurt-Camejo, E., Camejo, G., Rosengren, B., Lopez, F., Wiklund, O., & Bondjers, G. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42610-0 · Cited by 162
Dense low density lipoproteins and coronary artery disease
Krauss, R. M. (1995) · The American Journal of Cardiology · doi:10.1016/0002-9149(95)80012-h · Cited by 158 · cited 1×
“Individuals with a predominance of small, dense LDL have a 3–7-fold increase in myocardial infarction risk (48, 49).”
BackgroundSelf-citationQuantitative measurement of lipoprotein surface charge by agarose gel electrophoresis.
Sparks, D., & Phillips, M. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41889-9 · Cited by 150
Camejo, G., Fager, G., Rosengren, B., Hurt-Camejo, E., & Bondjers, G. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85218-3 · Cited by 143
Lund-Katz, S., Laplaud, P. M., Phillips, M. C., & Chapman, M. J. (1998) · Biochemistry · doi:10.1021/bi980828m · Cited by 143 · cited 2×
“Size and density of lipoproteins also can affect the accessibility and conformation of apoB and apoE on lipoproteins (7, 46 , 47).”
BackgroundOverexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice.
Shachter, N. S., Hayek, T., Leff, T., Smith, J. D., Rosenberg, D. W., Walsh, A., Ramakrishnan, R., Goldberg, I. J., Ginsberg, H. N., & Breslow, J. L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117151 · Cited by 139
Hollander, W. (1976) · Experimental and Molecular Pathology · doi:10.1016/0014-4800(76)90021-6 · Cited by 122
La Belle, M., & Krauss, R. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42342-9 · Cited by 118
Self-citationTriglyceride-rich lipoproteins and the progression of coronary artery disease
Hodis, H. N., & Mack, W. J. (1995) · Current Opinion in Lipidology · doi:10.1097/00041433-199508000-00004 · Cited by 117
Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.
Batal, R., Tremblay, M., Barrett, P. H. R., Jacques, H., Fredenrich, A., Mamer, O., Davignon, J., & Cohn, J. S. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32379-8 · Cited by 113
Self-citationFlotation rates, molecular weights and hydrated densities of the low‐density lipoproteins
Lindgren, F. T., Jensen, L. C., Wills, R. D., & Freeman, N. K. (1969) · Lipids · doi:10.1007/bf02531003 · Cited by 106
Le, N. A., Gibson, J. C., & Ginsberg, H. N. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38512-6 · Cited by 103
Olin, K. L., Potter-Perigo, S., Barrett, P. H. R., Wight, T. N., & Chait, A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34629 · Cited by 99 · cited 2×
“[ 35 S]SO 4 -biglycan was derived from cultured human arterial smooth muscle cells, as described previously ( 31 ).”
MethodSelf-citationTriglycerides, apo C3 and Lp B:C3 and cardiovascular risk in Type II diabetes
Gervaise, N., Garrigue, M. A., Lasfargues, G., & Lecomte, P. (2000) · Diabetologia · doi:10.1007/s001250051366 · Cited by 85
Mann, C. J., Troussard, A. A., Yen, F. T., Hannouche, N., Najib, J., Fruchart, J.-C., Lotteau, V., André, P., & Bihain, B. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31348 · Cited by 77 · cited 1×
“To test if adding exogenous apoC-III to lipoproteins might result in increased biglycan binding, equal protein levels of apoC-III (Academy Bio-Medical, Houston, TX) were added to VLDL or LDL as described previously (30).”
MethodProteoglycans and lipoproteins in atherosclerosis
Camejo, G., Hurt-Camejo, E., Olsson, U., & Bondjers, G. (1993) · Current Opinion in Lipidology · doi:10.1097/00041433-199310000-00007 · Cited by 71 · cited 1×
“Previous work has suggested that in human LDL, compositional parameters such as an elevated cholesterol-protein ratio, a low triglyceride-protein ratio, and a high isoelectric point increase its affinity for chondroitin sulfate proteoglycans (43, 44).”
BackgroundChen, G. C., Liu, W., Duchateau, P., Allaart, J., Hamilton, R. L., Mendel, C. M., Lau, K., Hardman, D. A., Frost, P. H., & Malloy, M. J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)62020-x · Cited by 71 · cited 1×
“Size and density of lipoproteins also can affect the accessibility and conformation of apoB and apoE on lipoproteins (7, 46, 47).”
BackgroundCharge properties of low density lipoprotein subclasses
Belle, M. L., Blanche, P. J., & Krauss, R. M. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37236-9 · Cited by 53
Self-citationCamejo, G., Rosengren, B., Olson, U., Lopez, F., Olofson, S.-O., Westerlund, C., & Bondjers, G. (1990) · European Heart Journal · doi:10.1093/eurheartj/11.suppl_e.164 · Cited by 50 · cited 1×
“These data are consistent with the idea that the interaction between lipoproteins and proteoglycans is ionic in nature, such that lipoproteins with greater positive charge bind better to negatively charged glycosaminoglycan side chains on proteoglycans (6, 7, 36).”
ResultBiglycan, a Vascular Proteoglycan, Binds Differently to HDL 2 and HDL 3: Role of ApoE
Olin, K. L., Potter-Perigo, S., Barrett, P. H. R., Wight, T. N., & Chait, A. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.1.129 · Cited by 45
Self-citationLiu, H., Talmud, P. J., Lins, L., Brasseur, R., Olivecrona, G., Peelman, F., Vandekerckhove, J., Rosseneu, M., & Labeur, C. (2000) · Biochemistry · doi:10.1021/bi0009441 · Cited by 42
Conformation of apolipoprotein E in lipoproteins.
Lund-Katz, S., Weisgraber, K. H., Mahley, R. W., & Phillips, M. C. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49418-0 · Cited by 40 · cited 1×
“croenvironments surrounding specific lysine residues, which affect apolipoprotein accessibility and LDLR binding (45, 46).”
BackgroundApolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size
Breyer, E. D., Le, N.-A., Li, X., Martinson, D., & Brown, W. V. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34904-x · Cited by 38
Proteoglycans and Potential Mechanisms Related to Atherosclerosisa
Berenson, G. S., Radhakrishnamurthy, B., Srinivasan, S. R., Vijayagopal, P., & Dalferes, E. R. (1985) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1985.tb11845.x · Cited by 34
Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice.
Jong, M., & Havekes, L. M. (2000) · PubMed · Cited by 26
Measurements of Proteoglycarwlipoprotein Interaction by Gel Mobility Shift Assay
Hurt-Camejo, E., Camejo, G., & Sartipy, P. (2003) · Lipoprotein Protocols · doi:10.1385/1-59259-582-0:267 · Cited by 25 · cited 1×
“The ability of lipoprotein preparations (whole lipoproteins or LDL subfractions) to bind purified biglycan was assessed using a modification of the gel mobility-shift assay described by Camejo et al (31, 34, 35).”
MethodGenetic Epidemiology of Dyslipidaemia and Atherosclerosis
Austin, M. A. (1996) · Annals of Medicine · doi:10.3109/07853899608999108 · Cited by 13 · cited 1×
“Individuals with a predominance of small, dense LDL have a 3‐7-fold increase in myocardial infarction risk (48, 49 ).”
Background
Cited by
Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
Self-citationGinsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
“in apoE and apoCIII, both implicated in binding and retention in the artery wall.(5,71,125) These factors enhance remnant cholesterol deposition in the plaque;(71,126,127) indeed, unlike LDL, remnant particle entry exceeds efflux.”
BackgroundBorén, J., & Williams, K. J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000330 · Cited by 524
“The mechanism has been unclear because apoC-III by itself lacks positively charged domains to bind arterial-wall proteoglycans [51].”
BackgroundNakashima, Y., Wight, T. N., & Sueishi, K. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn099 · Cited by 299
“LDL, very-low-density lipoprotein (VLDL), and intermediatedensity lipoprotein (IDL).(73) Overexpression of human biglycan by rat SMCs results in production of an ECM with increased high-affinity lipoprotein binding.”
BackgroundSelf-citationApolipoproteins in vascular biology and atherosclerotic disease
Mehta, A., & Shapiro, M. D. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00613-5 · Cited by 273
Metadata
- Authors
- Olin-Lewis, K., Krauss, R. M., La Belle, M., Blanche, P. J., Barrett, P. H. R., Wight, T. N., & Chait, A.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- The University of Western Australia (AU)
- University of Washington (US)
- Corresponding author
- Chait, Alan
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2002-11
- Volume
- 43
- Issue
- 11
- Pages
- 1969-1977
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2015816213
- Cited by
- 114
- References
- 54
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 10 · 2023: 6 · 2022: 4 · 2021: 7 · 2020: 10 · 2019: 2 · 2018: 5 · 2017: 1 · 2016: 7 · 2015: 3 · 2014: 3 · 2013: 2 · 2012: 6
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6514 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (HL30086)
- U.S. Public Health Service (12609)
- National Heart, Lung, and Blood Institute (P01HL030086, HL3-0086, HL 18754)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 02456, DK35816-16, P30DK035816)
- National Center for Research Resources
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Keywords
- apolipoprotein C-III, biglycan, apolipoprotein B, apolipoprotein E, VLDL, IDL, low-density lipoprotein, atherosclerosis, atherogenesis, arterial smooth muscle cells, immunoaffinity chromatography
- MeSH terms
- Apolipoproteins B, Apolipoproteins C, Chromatography, Affinity, Humans, Lipoproteins, Lipoproteins, LDL, Lipoproteins, VLDL, Particle Size, Proteoglycans, Extracellular Matrix Proteins, Apolipoprotein C-III, Biglycan
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.